Cargando…
Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
BACKGROUND: To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients with relapsing–remitting Multiple Sclerosis (MS). METHODS: Clinical and imaging data from patients treated with either IFNβ-1a or DMF for at...
Autores principales: | Sattarnezhad, Neda, Healy, Brian C., Baharnoori, Moogeh, Diaz-Cruz, Camilo, Stankiewicz, James, Weiner, Howard L., Chitnis, Tanuja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277810/ https://www.ncbi.nlm.nih.gov/pubmed/35820822 http://dx.doi.org/10.1186/s12883-022-02761-8 |
Ejemplares similares
-
Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
por: Baharnoori, Moogeh, et al.
Publicado: (2016) -
Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021) -
Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021) -
Cross-sectional study of smoking exposure: no differential effect on
OCT metrics in a cohort of MS patients
por: Rosso, Mattia, et al.
Publicado: (2019) -
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)